Celgene (NASDAQ:
CELGZ) moved up 100.84% to $6.25 in the pre-market session. Celgene's pancreatic cancer drug Abraxene improved overall survival rates in a phase III study.
Titanium Metals (NYSE:
TIE) surged 42.61% to $16.50 in the pre-market session. Precision Castparts (NYSE:
PCP) announced its plans to acquire Titanium Metals for around $2.9 billion.
Jefferies Group (NYSE:
JEF) added 20.51% to $17.16 in the pre-market session. Leucadia National (NYSE:
LUK) announced its plans to acquire Jefferies Group.
Gilead Sciences (NASDAQ:
GILD) soared 9.77% to $71.36 in the pre-market trading. Gilead Sciences announced positive results in mid-stage hepatitis C virus (HCV) infection study.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
